Brody myopathy
Rare disorder impairing muscle relaxation after exercise.
Brody myopathy, also known as Brody disease, is a rare condition impacting skeletal muscle. First described in 1969 by Dr. Irwin A. Brody at Duke University Medical Center, the disorder makes it hard for people to relax their muscles after physical activity. This leads to cramps, stiffness, and discomfort, particularly in the limbs and facial muscles.
Symptoms like stiffness and cramping—termed pseudo-myotonia—tend to worsen with exercise. The arms, legs, and eyelids are most commonly affected. Some individuals also experience muscle pain, weakness, or rhabdomyolysis, and a few develop a pseudoathletic appearance due to enlarged muscles.
Most cases are inherited in an autosomal recessive pattern, caused by mutations in the ATP2A1 gene. This gene codes for SERCA1, a protein pump in fast-twitch skeletal muscle that moves calcium ions from the cytosol into the sarcoplasmic reticulum using ATP. In Brody myopathy, faulty SERCA1 pumps cannot transport calcium effectively, leading to elevated calcium levels in the cytoplasm. This disrupts normal muscle contraction and produces the disorder’s hallmark symptoms. In some instances, no ATP2A1 mutations are found, and these cases follow an autosomal dominant inheritance pattern. This suggests genetic heterogeneity, meaning other, as-yet-unidentified genes may be involved.
Diagnosis begins with a clinical assessment for exercise-induced cramping and stiffness. Blood tests may show normal to slightly elevated creatine kinase levels. Muscle biopsies often reveal variation in fiber size, atrophied fast-twitch fibers, and an increased number of nuclei. Electromyography (EMG) helps rule out true myotonia, as people with Brody myopathy have stiff muscles but normal EMG results (pseudo-myotonia), with no myotonic discharges. Genetic testing can confirm mutations in ATP2A1.
There is no cure, but treatments can reduce symptoms. The drug dantrolene is used as a muscle relaxant by inhibiting calcium release channels in the sarcoplasmic reticulum, limiting the amount of calcium released into the cytoplasm. Normally, when a muscle is stimulated, calcium is released from the sarcoplasmic reticulum into the cytoplasm, where it binds to
- first characterized
- 1969
- characterized by
- Dr. Irwin A. Brody
- institution
- Duke University Medical Center
- inheritance pattern
- autosomal recessive (most cases); autosomal dominant (some non-ATP2A1 cases)
- affected gene
- ATP2A1 (most cases)
- encoded protein
- SERCA1
- key symptom
- difficulty relaxing muscles after exercise
Lore & Background
Brody myopathy was first characterized in 1969 by Dr. Irwin A. Brody at Duke University Medical Center. The disorder primarily affects skeletal muscle function, with symptoms including stiffness, cramping, and discomfort in the arms, legs, and eyelids, especially after exercise. The condition is generally considered non-progressive or only slowly progressive. Some individuals also experience weakness, myalgia, rhabdomyolysis, or a pseudoathletic appearance with hypertrophic muscles.
Reader's Guide
Brody myopathy is significant as a rare genetic disorder that highlights the critical role of calcium regulation in muscle contraction. Most cases are caused by autosomal recessive mutations in ATP2A1, which encodes the SERCA1 protein pump responsible for moving calcium ions from the cytosol into the sarcoplasmic reticulum. When SERCA1 is defective, calcium accumulates in the cytoplasm, leading to prolonged muscle contraction and the characteristic stiffness. Diagnosis involves clinical evaluation, blood tests for creatine kinase, muscle biopsy showing fiber size variation and atrophy, and electromyography to rule out myotonia. Genetic testing for ATP2A1 mutations can confirm the diagnosis. Treatment focuses on symptom management with drugs like dantrolene and verapamil, which limit calcium release from the sarcoplasmic reticulum. There is no cure, and the condition's genetic heterogeneity suggests other loci may be involved, though none have been identified.
Did You Know?
- Brody myopathy was first characterized in 1969 by Dr. Irwin A. Brody at Duke University Medical Center.
- The disorder is caused by mutations in the ATP2A1 gene, which impairs calcium handling in fast-twitch muscle fibers.
- Dantrolene, a muscle relaxant that inhibits calcium release channels, is sometimes used to manage symptoms.
More in Genetic diseases and disorders 1-24
Spotted an error? Know more?
This is a living reference — every entry is fact-audited, and reader corrections feed straight into our audit queue. Suggest an edit · See this site's audit record